Genetic Polymorphisms of CFH and ARMS2 Do Not Predict Response to Antioxidants and Zinc in Patients with Age-Related Macular Degeneration: Independent Statistical Evaluations of Data from the Age-Related Eye Disease Study

scientific article published on 9 October 2017

Genetic Polymorphisms of CFH and ARMS2 Do Not Predict Response to Antioxidants and Zinc in Patients with Age-Related Macular Degeneration: Independent Statistical Evaluations of Data from the Age-Related Eye Disease Study is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/J.OPHTHA.2017.09.008
P932PMC publication ID5820191
P698PubMed publication ID29032853

P50authorFan LiQ57036756
P2093author name stringAndrew J Vickers
Ying Wang
Keith A Baggerly
Andrew S Allen
Melissa J Assel
P2860cites workA randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8Q24544001
No clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38Q34620551
Genetic testing in persons with age-related macular degeneration and the use of the AREDS supplements: to test or not to test?Q34778837
A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancerQ38278153
CFH and ARMS2 genetic polymorphisms predict response to antioxidants and zinc in patients with age-related macular degenerationQ43953153
Author reply: To PMID 24974817.Q44581716
Treatment response to antioxidants and zinc based on CFH and ARMS2 genetic risk allele number in the Age-Related Eye Disease StudyQ44915960
Response to AREDS supplements according to genetic factors: survival analysis approach using the eye as the unit of analysis.Q51608120
CFH and LOC387715/ARMS2 genotypes and treatment with antioxidants and zinc for age-related macular degenerationQ81117261
Re: Chew et al.: No clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38 (Ophthalmology 2014;121:2173-80)Q85650478
Should we test for genotype in deciding on age-related eye disease study supplementation?Q86411240
P921main subjectstatisticsQ12483
eye diseaseQ3041498
macular degenerationQ27429789
P577publication date2017-10-09
P1433published inOphthalmologyQ7098109
P1476titleGenetic Polymorphisms of CFH and ARMS2 Do Not Predict Response to Antioxidants and Zinc in Patients with Age-Related Macular Degeneration: Independent Statistical Evaluations of Data from the Age-Related Eye Disease Study

Reverse relations

cites work (P2860)
Q47567166CFH and ARMS2 genetic risk determines progression to neovascular age-related macular degeneration after antioxidant and zinc supplementation
Q52559837Exploring the Use of Molecular Biomarkers for Precision Medicine in Age-Related Macular Degeneration.
Q93102835Nutrients for Prevention of Macular Degeneration and Eye-Related Diseases
Q64956915Pharmacogenomics of antioxidant supplementation to prevent age-related macular degeneration.
Q64124312Reply to Vickers: Pharmacogenetics and progression to neovascular age-related macular degeneration-Evidence supporting practice change
Q92751432Serum 25-Hydroxyvitamin D Concentrations and Incidence of Age-Related Macular Degeneration: The Atherosclerosis Risk in Communities Study

Search more.